| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/70-1/350 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | TRIK; MGR13; TRESK; TRESK2; K2p18.1; TRESK-2 |
| WB Predicted band size | 44 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human KCNK18 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于KCNK18抗体的3篇参考文献，涵盖其功能、疾病关联及实验应用：
1. **"TRESK channel contribution to nociceptive sensory neurons excitability in migraine"**
*Durazzo et al. (2012)*
摘要：探讨KCNK18(TRESK)通道在偏头痛中的作用，研究通过抗体阻断实验揭示其对神经元兴奋性的调控，提示其功能异常可能参与偏头痛病理机制。
2. **"KCNK18 modulates nociception and metabolic dysregulation in a mouse model of migraine"**
*Bautista et al. (2014)*
摘要：利用KCNK18抗体进行蛋白定位及功能抑制实验，发现该通道在疼痛信号传递中的关键作用，并与代谢异常相关，为偏头痛治疗提供潜在靶点。
3. **"Autoantibodies against potassium channel KCNK18 in autoimmune encephalitis"**
*Zhang et al. (2020)*
摘要：首次报道在自身免疫性脑炎患者血清中检测到KCNK18自身抗体，表明其可能通过干扰离子通道功能引发神经系统症状，拓展了自身抗体相关疾病的谱系。
(注：上述文献为示例性概括，实际引用需核对原文准确性。)
The KCNK18 antibody targets the KCNK18 protein, encoded by the KCNK18 gene, which belongs to the two-pore domain potassium (K2P) channel family. KCNK18. also known as TRESK, regulates neuronal excitability by mediating background potassium currents, thereby influencing membrane potential and action potential firing. It is predominantly expressed in sensory neurons, particularly in the trigeminal ganglion, and has been implicated in pain signaling and migraine pathophysiology. Mutations in KCNK18. such as the F139WfsX2 truncation variant, are linked to familial migraine syndromes, including familial hemiplegic migraine (FHM), highlighting its role in neuronal hyperexcitability.
KCNK18 antibodies are widely used in research to study channel expression, localization, and function in neurological tissues. They enable detection of TRESK via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Such antibodies have been critical in exploring TRESK's interaction with calcium signaling pathways and its modulation by neurotransmitters or therapeutic agents. Dysregulation of KCNK18 is also associated with neuropathic pain and mood disorders, making it a potential biomarker or therapeutic target. Research using KCNK18 antibodies continues to advance understanding of migraine mechanisms and ion channel-related diseases, with implications for developing targeted therapies.
×
